Provided by Tiger Trade Technology Pte. Ltd.

Tempus AI

55.93
-2.3000-3.95%
Pre-market: 55.50-0.4300-0.77%05:00 EDT
Volume:4.14M
Turnover:233.91M
Market Cap:10.03B
PE:-32.46
High:57.95
Open:57.64
Low:54.50
Close:58.23
52wk High:104.32
52wk Low:41.73
Shares:179.40M
Float Shares:114.00M
Volume Ratio:0.92
T/O Rate:3.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7231
EPS(LYR):-1.4100
ROE:-81.58%
ROA:-9.07%
PB:24.10
PE(LYR):-39.67

Loading ...

Tempus AI Price Target Maintained With a $80.00/Share by BTIG

Dow Jones
·
Jun 01

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Tempus AI, Inc. Class A (TEM) and Incyte (INCY)

TIPRANKS
·
Jun 01

Tempus AI Launches Next-Generation Agentic AI Platform for Oncology Drug Development

MT Newswires Live
·
Jun 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus AI, Inc. Class A (TEM)

TIPRANKS
·
Jun 01

Short Report: Tempus AI short interest at record high

TIPRANKS
·
Jun 01

Consumer Tech News (May 25-29): Dell, IBM, CrowdStrike, Meta Lead Big Tech AI Push

Benzinga
·
May 31

Tempus AI announces launch of PRECISION Challenge for oncology breakthroughs

TIPRANKS
·
May 31

Tempus AI announces introduction of Tempus Preview

TIPRANKS
·
May 31

Tempus AI CEO and Chairman Eric Lefkofsky reports sale of 166,250 common shares worth $7.76 million

Reuters
·
May 30

AI Application Software Shares Extended Gains. Palantir Up 10%; Salesforce And Rubrik Up 8%; Snowflake, GitLab And HubSpot Up 6%

Tiger Newspress
·
May 29

Tempus AI expects 25% top-line growth over next 3 years

TIPRANKS
·
May 29

Tempus AI reiterates FY26 revenue view of $1.59B-$1.6B, consensus $1.59B

TIPRANKS
·
May 29

Tempus AI announces initial results from Multimodal Foundation Model efforts

TIPRANKS
·
May 29

BUZZ-U.S. STOCKS ON THE MOVE-Tempus AI, SOLV Energy, Replimune

Reuters
·
May 29

Tempus AI posts investor day presentation on AI-driven diagnostics, precision-medicine data platform

Reuters
·
May 29

Sector Update: Healthcare

MT Newswires Live
·
May 29

BUZZ-Tempus AI rises after securing FDA approval for tumor test

Reuters
·
May 29

Tempus AI Shares up 7.3% Premarket After FDA Approves Its Xt Cdx Test for Genetic Profiling of Tumors

THOMSON REUTERS
·
May 29

Movement Alert|Tempus AI Rises 5.77% in Pre-Market Trading, Oncology Xt Companion Diagnostic Product Receives FDA Approval

Market Focus
·
May 29

Stock Track | Tempus AI Soars 5.05% Pre-Market on FDA Approval for Tumor Diagnostic

Stock Track
·
May 29